Literature DB >> 18397786

Plasmodium chabaudi: efficacy of artemisinin + curcumin combination treatment on a clone selected for artemisinin resistance in mice.

Axel Martinelli1, Louise A Rodrigues, Pedro Cravo.   

Abstract

Recent studies have proposed curcumin as a potential partner for artemisinin in artemisinin combination therapies to treat malaria infections. The efficacy of curcumin alone and in combination with artemisinin was evaluated on a clone of Plasmodium chabaudi selected for artemisinin resistance in vivo. The addition of piperine as an enhancer of curcumin activity was also tested. Results indicated that curcumin, both alone and in combination with piperine had only a modest antimalarial effect and was not able to reverse the artemisinin-resistant phenotype or significantly affect growth of the tested clone when used in combination with artemisinin. This is in contrast with previous in vivo work and calls for further experimental evaluation of the antimalarial potential of curcumin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18397786     DOI: 10.1016/j.exppara.2008.02.011

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  10 in total

Review 1.  Genetic analysis in mice identifies cysteamine as a novel partner for artemisinin in the treatment of malaria.

Authors:  Gundula Min-Oo; Philippe Gros
Journal:  Mamm Genome       Date:  2011-03-25       Impact factor: 2.957

Review 2.  Effects of Curcumin and Its Analogues on Infectious Diseases.

Authors:  Reza Ranjbar; Hossein Bagheri; Faezeh Ghasemi; Paul C Guest; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Toxoplasma histone acetylation remodelers as novel drug targets.

Authors:  Laura Vanagas; Victoria Jeffers; Silvina S Bogado; Maria C Dalmasso; William J Sullivan; Sergio O Angel
Journal:  Expert Rev Anti Infect Ther       Date:  2012-10       Impact factor: 5.091

Review 4.  The plant-based immunomodulator curcumin as a potential candidate for the development of an adjunctive therapy for cerebral malaria.

Authors:  Patrice N Mimche; Donatella Taramelli; Livia Vivas
Journal:  Malar J       Date:  2011-03-15       Impact factor: 2.979

5.  Curcumin-arteether combination therapy of Plasmodium berghei-infected mice prevents recrudescence through immunomodulation.

Authors:  Palakkod G Vathsala; Chaitanya Dende; Viswanathan Arun Nagaraj; Debapriya Bhattacharya; Gobardhan Das; Pundi N Rangarajan; Govindarajan Padmanaban
Journal:  PLoS One       Date:  2012-01-20       Impact factor: 3.240

6.  Antiplasmodial Activity and Toxicological Assessment of Curcumin PLGA-Encapsulated Nanoparticles.

Authors:  Zulaikha A Busari; Kabiru A Dauda; Olajumoke A Morenikeji; Funmilayo Afolayan; Oyetunde T Oyeyemi; Jairam Meena; Debasis Sahu; Amulya K Panda
Journal:  Front Pharmacol       Date:  2017-09-06       Impact factor: 5.810

7.  Oral Administration of Piperine as Curative and Prophylaxis Reduces Parasitaemia in Plasmodium berghei ANKA-Infected Mice.

Authors:  Shafia Khairani; Nisa Fauziah; Hesti Lina Wiraswati; Ramdan Panigoro; Endang Yuni Setyowati; Afiat Berbudi
Journal:  J Trop Med       Date:  2022-03-22

8.  Piperine Enhances the Antimalarial Activity of Curcumin in Plasmodium berghei ANKA-Infected Mice: A Novel Approach for Malaria Prophylaxis.

Authors:  Shafia Khairani; Nisa Fauziah; Hesti Lina Wiraswati; Ramdan Panigoro; Annas Salleh; Endang Yuni Setyowati; Afiat Berbudi
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-05       Impact factor: 2.650

9.  Treatment of Plasmodium chabaudi Parasites with Curcumin in Combination with Antimalarial Drugs: Drug Interactions and Implications on the Ubiquitin/Proteasome System.

Authors:  Zoraima Neto; Marta Machado; Ana Lindeza; Virgílio do Rosário; Marcos L Gazarini; Dinora Lopes
Journal:  J Parasitol Res       Date:  2013-04-03

Review 10.  Modulation of cerebral malaria by curcumin as an adjunctive therapy.

Authors:  Kunal Jain; Sumeet Sood; K Gowthamarajan
Journal:  Braz J Infect Dis       Date:  2013-07-29       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.